Lilly stock rises after drugmaker reports higher sales
Investors responded favorably Thursday to Eli Lilly and Co.’s surprisingly strong second-quarter revenue, even though its profit fell due to rapid spending on marketing and research.
Public Companies
Articles
Pfizer won’t break up animal unit for potential Lilly bid
Pfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
ITT Educational continues enrollment, profit slide
In the second quarter, the Carmel-based operator of for-profit colleges saw enrollment drop 19.9 percent and profit sink 17.7 percent. But the company posted strong earnings per share by continuing to buy back shares.
Lilly profit falls, but forecast rises after second quarter
Second-quarter profit fell at Eli Lilly and Co., but the Indianapolis drugmaker beat the estimates of Wall Street analysts by a penny per share and raised its full-year profit forecast by as much as 10 cents per share.
Emmis’ local radio stations get big lift from new ratings system
During the quarter ended May 31, ratings at Emmis Communications’ four local stations greatly outpaced other stations in the market.
Emmis reports larger quarterly loss, higher revenue
For the quarter ended May 31, Emmis suffered a loss of $4.5 million, or 12 cents a share, compared with a loss of $3.9 million, or 10 cents a share, in the same period last year.
Cummins CEO Solso retiring at end of year
Cummins Inc. says Tim Solso will retire as chairman and CEO at the end of the year. The 64-year-old Solso has led Cummins since 2000.
Simon Property Group signs CEO to long-term contract
Indianapolis-based Simon Property Group Inc. signed an employment agreement with CEO David Simon that will keep him as head of the largest U.S. mall owner for the next eight years—and give him a one-time award worth $120 million.
Outgoing CEO: After ‘near-death experience,’ CNO doing well
CEO Jim Prieur got more than he bargained for when he took over CNO Financial Group (then-Conseco) five years ago, but he said he’s ready to step down now that the insurer is in good shape.
Lilly asks judge to reject U.K. Zyprexa case
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
Rolls-Royce upgrades engine on market since 1950s
Rolls-Royce’s Indianapolis plant assembles few of its workhorse T56 aircraft engines in whole, but cranking out spare parts for overhauls is a large business. The last contract modification, issued by the U.S. Air Force in 2007, is worth up to $789 million and is still active.
Lilly plans 10 drugs in final-stage trials by year’s end
Lilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s disease, up from seven in 2005, the Indianapolis-based company said Thursday.
Future bleak for Arcadia as cash crunch forces sale of business unit
Indianapolis-based Arcadia Resources Inc.’s auditor issued a “going-concern” warning Tuesday in the once-promising company’s annual report.
Lilly plans more investment in two-in-one drugs
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
Emmis selling three major radio stations
Emmis Communications Corp. has reached an agreement to sell three big-market radio stations to a partnership involving a private equity firm and a prominent media executive, the company disclosed Tuesday morning.
Sources: Angie’s List picks adviser to handle planned August IPO
Angie’s List Inc., a website that provides consumer reviews of plumbers, electricians and other services, is preparing to file in August for an initial public offering, said two people with direct knowledge of the plans.
Analyst: Lilly drug poised for continued growth
Eli Lilly and Co.'s lung cancer treatment Alimta is poised for continued growth based on recently released study data, according to a new Credit Suisse analyst report.
State’s private companies performed unevenly last year
Fewer than half generated revenue increases.
Indiana public companies had banner year
Corporations staged advances across a variety of industries in 2010 as the economy improved.
2010 was great for Indiana’s 100 largest companies
Despite enjoying rising revenues and profits, companies haven’t followed with big increases in job numbers.